Home Favorites Papers Resume Photo Album


Bibliography for Michael Piette

712 E. Court St.

Janesville, WI 53545-4015



Michael has spent part of his career in academia, and the following is a list of the papers that have come of it:


  • “Metabolism of Antiestrogens”  in Estrogens and Antiestrogens.  Jordan, V. Craig, Michael Piette, and Angela Cisneros.  Lippincott-Raven Publishers, Philadelphia, 1997  (this is a book chapter, not a journal article)

  • “Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.”  O’Regan, R. M., M. M. Bilimoria, A. Cisneros, M. Piette, G. M. England, Y. P. Dragan, J. I. Macgregor , H. C. Pitot, H. D. Muenzner, R. Chatterton, V. J. Assikis, V. C. Jordan.  Journal of the National Cancer Institute (Bethesda) 90(20) 1998. 1552-1558

  • “Pathology of female rats after chronic administration of tamoxifen or toremifene.”  Dragan, Y. P., J. R. Vaughan, A. Cisneros, V. C. Jordan, M. Piette, H. C. Pitot. 20th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 3-6, 1997. Breast Cancer Research & Treatment 46(1) 1997. 85

  • “A Phase II Clinical Trial of Suramin for the Treatment of Patients with Metastatic Breast Cancer,” in process

  • “Optimization of Automated Solid Phase Extraction Methods.”  Urban-Piette, Michael and Paul Bouis.  Podium presentation at Pittsburgh Conference 1999, Orlando, Florida

  • “Automated SPE of Tricyclic Antidepressants”.  Urban-Piette, Michael, Gary Lensmeyer and Lynn Stroede.  From poster session 200 “Sample Handling/Automation/Polymers and Plastics”.  Pittsburgh Conference 1999, Orlando, Florida

  • “Densitometry of ex vivo Mouse Long Bones”, Lopez Franco, Gloria E, Tyriina K O’Neil, Suzanne J Litscher, Michael Piette, Robert D Blank.  Journal of Clinical Densitometry.  (paper accepted as of Jan 2004)






J Natl Cancer Inst. 1998 Oct 21;90(20):1552-8.


Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.


O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC.


Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA.


BACKGROUND: Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer. The effects of these drugs on endometrial cancer are currently unknown. Our objective was to evaluate the effects of toremifene and ICI 182,780 on the growth of human endometrial cancer in athymic mice. METHODS: Athymic, ovariectomized mice were implanted with human endometrial tumors and treated with estrogen, tamoxifen, or the new antiestrogens. RESULTS: The effects of tamoxifen and toremifene on the growth of either tamoxifen-stimulated or tamoxifen-naive endometrial tumors in athymic mice were not substantially different. ICI 182,780 inhibited the growth of tamoxifen-stimulated endometrial cancer, in both the presence and the absence of estrogen. CONCLUSIONS: Toremifene and tamoxifen produce identical effects in our endometrial cancer models. Therefore, it is possible that toremifene, like tamoxifen, may be associated with an increased incidence of endometrial cancer. In contrast, ICI 182,780 inhibited tamoxifen-stimulated endometrial cancer, both in the presence and in the absence of estrogen, suggesting that this drug may be safe with regard to the endometrium, even if it is used following tamoxifen, and that it may not result in an increased incidence of endometrial cancer. Indeed, it is even possible that ICI 182,780 may prove useful as an adjuvant agent in early stage endometrial cancer.